Figure 2 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies

Key Points

• HER2 expression varies significantly between prostate cancer and urothelial carcinoma, impacting therapy decisions.
• Analysis indicates clear correlations between ERBB2 genomic status and HER2 IHC across both cancer types.
• Box plots demonstrate relationships between HER2 RNA expression and cancer types, highlighting diagnostic potentials.
• Understanding HER2 can guide targeted therapies for prostate and urothelial cancers, supporting personalized treatments.